Zuben E. Sauna

Zuben E. Sauna

Auto-generated profile, based on publicly available information

Zuben E. Sauna

Division of Hemostasis, Office of Plasma Protein Therapeutics, Office of Therapeutic Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2011 in Nature Reviews Genetics
Verified
Journal Article
Closed access
ZSZuben E. Sauna
Zuben E. Sauna
CKChava Kimchi-Sarfaty
Chava Kimchi-Sarfaty

7 February 2017 in F1000Research
Verified
Journal Article
Open access
PDF file
HLH.A. Daniel Lagassé
H.A. Daniel Lagassé
AAAikaterini Alexaki
Aikaterini Alexaki
VSVijaya L. Simhadri
Vijaya L. Simhadri
NKNobuko H. Katagiri
Nobuko H. Katagiri
WJWojciech Jankowski
Wojciech Jankowski
CKChava Kimchi-Sarfaty
Chava Kimchi-Sarfaty
Therapeutic protein drugs are an important class of medicines serving patients most in need of novel therapies. Recently approved recombinant protein therapeutics have been developed to treat a wide variety of clinical indications, including cancers, autoimmunity/inflammation, exposure to infectious agents, and genetic disorders. The latest advances in protein-engineering technologies have allowed drug developers and manufacturers to fine-tune and exploit desirable functional characteristics of proteins of interest while maintaining (and in some cases enhancing) product safety or efficacy or both. In this review, we highlight the emerging trends and approaches in protein drug development by using examples of therapeutic proteins approved by the U.S. Food and Drug Administration over the previous five years (2011–2016, namely January 1, 2011, through August 31, 2016).

1 July 2014 in Trends in Genetics
Verified
Journal Article
Closed access
RHRyan C. Hunt
Ryan C. Hunt
VSVijaya L. Simhadri
Vijaya L. Simhadri
MIMatthew Iandoli
Matthew Iandoli
ZSZuben E. Sauna
Zuben E. Sauna
CKChava Kimchi-Sarfaty
Chava Kimchi-Sarfaty

1 September 2018 in Molecular Therapy - Methods & Clinical Development
Verified
Journal Article
Open access
VSVijaya L. Simhadri
Vijaya L. Simhadri
JMJoseph McGill
Joseph McGill
SMShane McMahon
Shane McMahon
JWJunxia Wang
Junxia Wang
HJHaiyan Jiang
Haiyan Jiang
ZSZuben E. Sauna
Zuben E. Sauna
The repurposing of the CRISPR/Cas microbial adaptive immune system for gene editing has resulted in an exponential rise in new technologies and promising approaches for treating numerous human diseases. While some of the approaches being currently developed involve ex vivo editing by CRISPR/Cas9, many more potential applications will require in vivo editing. The in vivo use of this technology comes with challenges, one of which is the immune response to Cas9, a protein of microbial origin. Thus, the prevalence of pre-existing antibodies to Cas9 could also be a relevant parameter. There are many avenues for how CRISPR/Cas9 technologies will be applied in vivo, including the mode of delivery. These may be expected to invoke different immunological pathways. Nonetheless, as with all protein therapeutics, it may be desirable to monitor for anti-Cas9 antibodies during clinical development. This will require the development of robust and reliable assays. Here, we describe ELISA-based assays that are capable of detecting antibodies to Cas9 from Staphylococcus aureus (SaCas9) and Streptococcs pyogenes (SpCas9) in human sera. Furthermore, using these assays to screen for pre-existing antibodies in 200 human serum samples, we found the prevalence of anti-SaCas9 and anti-SpCas9 antibodies to be 10% and 2.5%, respectively.

1 January 2015 in Trends in Biotechnology
Verified
Journal Article
Closed access
DLDitza Levin
Ditza Levin
BGBasil Golding
Basil Golding
SSScott E. Strome
Scott E. Strome
ZSZuben E. Sauna
Zuben E. Sauna

1 May 2018 in Journal of Pharmacy and Pharmacology
Verified
Journal Article
Open access
PDF file
ARAmy S. Rosenberg
Amy S. Rosenberg
ZSZuben E Sauna
Zuben E Sauna
Objective: Here we provide a critical review of the state of the art with respect to non-clinical assessments of immunogenicity for therapeutic proteins. Key findings: The number of studies on immunogenicity published annually has more than doubled in the last 5 years. The science and technology, which have reached a critical mass, provide multiple of non-clinical approaches (computational, in vitro, ex vivo and animal models) to first predict and then to modify or eliminate T-cell or B-cell epitopes via de-immunization strategies. We discuss how these may be used in the context of drug development in assigning the immunogenicity risk of new and marketed therapeutic proteins. Summary: Protein therapeutics represents a large share of the pharma market and provide medical interventions for some of the most complex and intractable diseases. Immunogenicity (the development of antibodies to therapeutic proteins) is an important concern for both the safety and efficacy of protein therapeutics as immune responses may neutralize the activity of life-saving and highly effective protein therapeutics and induce hypersensitivity responses including anaphylaxis. The non-clinical computational tools and experimental technologies that offer a comprehensive and increasingly accurate estimation of immunogenic potential are surveyed here. This critical review also discusses technologies which are promising but are not as yet ready for routine use.